Xcout Intel
Prostatype Genomics
Prostatype Genomics develops, manufactures, and markets Prostatype, a prognostic genetic test for prostate cancer. The test combines gene expression data with clinical parameters to assess cancer aggressiveness and help doctors and patients determine appropriate treatment decisions.
Subscribe to see Prostatype Genomics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Prostatype Genomics at a glance
Prostatype Genomics is a health care company headquartered in Sweden. Xcout tracks 6 named people at Prostatype Genomics, including Anders Liljeblad (Chariman of the Board).
Prostatype Genomics leadership
- Anders LiljebladChariman of the Board
- Anders LundbergBoard member
- Dr. Michael HäggmanBoard Member
- Håkan EnglundBoard Member
- Jörgen DahlströmBoard member
- Mattias PrageBoard Member
Prostatype Genomics competitors
A few of Prostatype Genomics's closest competitors — see the full list of competitors and alternatives →
A3P Biomedical is a Swedish private diagnostics company that specializes in advanced prostate cancer screening. Its lead product, Stockholm3, combines protein markers, genetic markers, and clinical data using an advanced algorithm to detect aggressive prostate cancer.
EarlyDiagnostics, also known as EarlyDx, is a clinical-stage precision diagnostics company that develops non-invasive liquid biopsy technologies and genomics platforms for early cancer detection.
Cyted Health delivers a diagnostic platform that combines minimally invasive cell collection with high-resolution molecular analysis. This platform is designed to detect early biological markers.
Orchid Health, Inc. provides whole-genome embryo screening services for individuals and couples undergoing in vitro fertilization (IVF). The company's testing evaluates embryos for genetic predispositions to thousands of conditions, including cancers, neurodevelopmental disorders, and heart defects, to help patients mitigate hereditary health risks.
Innocras is a genomic analysis and cancer big data company founded in South Korea by physician-scientists from KAIST, maintaining research and corporate presence in both the United States and Korea. The company specializes in advanced cancer diagnostics and genomic technology to support precision oncology.
4baseCare is an Illumina-backed company headquartered in Singapore, focused on developing cutting-edge Precision Oncology Solutions using Advanced Genomics. The company also provides free NGS-biomarker testing for eligible lung cancer patients across India.
Get Prostatype Genomics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Prostatype Genomics in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access